Vanguard Global Advisers
AMRX icon

Vanguard Global Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Vanguard Global Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
80,334
-26,220
-25% -$359K ﹤0.01% 1531
2026
Q1 		$1.32M Buy
+106,554
New +$1.43M ﹤0.01% 1461

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Global Advisers's AMRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Amneal Pharmaceuticals (AMRX) stake by 25% in Q2 2026, selling an estimated $359K and leaving 80,334 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Vanguard Global Advisers first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Vanguard Global Advisers held 80,334 shares of Amneal Pharmaceuticals worth $1.39M as of Q2 2026.
  • Vanguard Global Advisers sold 26,220 Amneal Pharmaceuticals shares in Q2 2026, an estimated $359K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1531 holding.
  • Vanguard Global Advisers first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.